AAHRPP Releases 2010 Metrics on Human Research Protection Programs Performance
Improving the quality of human research protection programs is a top priority for AAHRPP. Effective and efficient systems of oversight within organizations provide better protections for research participants and produce higher quality research. And collectively, they raise the bar globally to ensure research participants are safe and respected.
From data supplied by client organizations in 2010, AAHRPP has compiled an information database to help research organizations, researchers, sponsors, government agencies, and participants identify and support high-performing practices for human research protection programs (HRPPs).
Published here are the 2010 metrics for HRPP performance. The data range from types of research and conformance with regulations and guidance to financial and personnel resources and IRB review times.
A PDF version of the 2010 metrics will be available shortly. The 2009 metrics are available on the Website here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
